1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Acromegaly and Gigantism: Executive Summary
2.1 Steady Growth Expected in the Acromegaly and Gigantism Market from 2019-2029
2.2 Pharmaceutical Companies Are Focused on Developing Self-Administrable, Convenient Therapies
2.3 Polypharmacy Will Become Increasingly Common in the Magement of Patients With Intractable Disease
2.4 Lack of Disease Awareness Causing Delays in Diagnosis Is a Globally Prevalent Unmet Need
2.5 Oral Therapies and Long-Acting Injectable Somatostatin Receptor Agonists Will Become Top-Selling New Market Entrants in 2029
2.6 What Do Physicians Think?

3 Introduction
3.1 Catalyst
3.2 Related Reports

4 Disease Overview
4.1 Etiology and Pathophysiology
4.1.1 Etiology
4.1.2 Pathophysiology
4.2 Classification or Staging Systems
4.3 Prognosis and Quality of Life

5 Epidemiology
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.4 Forecast Methodology
5.4.1 Sources
5.4.2 Forecast Assumptions and Methods
5.4.3 Diagnosed Prevalent Cases of Acromegaly and Gigantism
5.4.4 Diagnosed Prevalent Cases of Acromegaly and Gigantism with Macroadenoma
5.4.5 Diagnosed Prevalent Cases of Acromegaly and Gigantism with Diabetes
5.4.6 Diagnosed Prevalent Cases of Acromegaly and Gigantism with Cardiovascular Disease
5.4.7 Diagnosed Prevalent Cases of Acromegaly and Gigantism with Hypertension
5.5 Epidemiological Forecast for Acromegaly, 2019-2029
5.5.1 Diagnosed Prevalent Cases of Acromegaly
5.5.2 Sex-Specific Diagnosed Prevalent Cases of Acromegaly
5.5.3 Age-Specific Diagnosed Prevalent Cases of Acromegaly
5.5.4 Diagnosed Prevalent Cases of Acromegaly with Macroadenoma
5.5.5 Diagnosed Prevalent Cases of Acromegaly with Comorbidities
5.5.6 Diagnosed Prevalent Cases of Gigantism
5.5.7 Sex-Specific Diagnosed Prevalent Cases of Gigantism
5.5.8 Age-Specific Diagnosed Prevalent Cases of Gigantism
5.5.9 Diagnosed Prevalent Cases of Gigantism with Macroadenoma
5.5.10 Diagnosed Prevalent Cases of Gigantism with Comorbidities
5.6 Discussion
5.6.1 Epidemiological Forecast Insight
5.6.2 Limitations of Alysis
5.6.3 Strengths of Alysis

6 Disease Magement
6.1 Overview
6.2 Diagnosis
6.3 Treatment
6.3.1 Treatment Guidelines
6.3.2 Non-pharmacotherapeutic Treatment Options
6.3.3 Pharmacotherapy
6.4 US
6.5 5EU
6.6 Cada

7 Competitive Assessment
7.1 Overview

8 Unmet Needs and Opportunity Assessment
8.1 Overview
8.2 Increasing Disease Awareness Among Patients and Physicians
8.3 Greater Control Over Treatment-Related Costs Blocking Access to Essential Therapies
8.4 Improving the Efficacy and Side-Effect Profiles of Pharmaceutical Products
8.5 Making Drug Administration More Mageable for Patients

9 Pipeline Assessment
9.1 Overview
9.2 Somatostatin Receptor Agonists
9.3 Antisense Therapy Growth Hormone Receptor Inhibitors
9.4 Early-Stage Pipeline Products

10 Current and Future Players

11 Market Outlook
11.1 Global Markets
11.1.1 Forecast
11.1.2 Drivers and Barriers - Global Issues
11.2 US
11.2.1 Forecast
11.2.2 Key Events
11.2.3 Drivers and Barriers
11.3 5EU
11.3.1 Forecast
11.3.2 Key Events
11.3.3 Drivers and Barriers
11.4 Cada
11.4.1 Forecast
11.4.2 Key Events
11.4.3 Drivers and Barriers

12 Appendix